Zhanna Belaya , Elena Przhiyalkovskaya , Elizaveta Mamedova , Sofia Gronskaia , Natalia Tarbaeva , Margarita Sharova , Sergey Popov , Michael Lewiecki
{"title":"Bone Health ECHO Case Report: High Bone Mass in a Patient with Chronic Kidney Disease","authors":"Zhanna Belaya , Elena Przhiyalkovskaya , Elizaveta Mamedova , Sofia Gronskaia , Natalia Tarbaeva , Margarita Sharova , Sergey Popov , Michael Lewiecki","doi":"10.1016/j.jocd.2024.101554","DOIUrl":null,"url":null,"abstract":"<div><div>Bone Health ECHO (Extension of Community Healthcare Outcomes) is a growing family of online educational programs. Its mission is to enhance delivery of best practice skeletal healthcare worldwide. Each program typically consists of a didactic lecture and discussion of clinical cases with diagnostic and treatment dilemmas. Here we present a Bone Health ECHO case of a 39-year-old man who has received hemodialysis for 12 years. This case is characterized by the development of chronic kidney disease - mineral and bone disorder (CKD-MBD) which was managed using conservative treatment to maintain phosphate and calcium levels within the reference range in spite of severe secondary hyperparathyroidism, after the patient declined parathyroidectomy. Although this patient had multiple vertebral fractures with height loss, his bone mineral density was higher than expected for his age and gradually increased over the period of observation. Whole-exome sequencing showed a heterozygous, likely pathogenic variant in <em>LEMD3</em> gene (13 exon HG38, chr12:65246271dup, с.2682dup in a heterozygous state), which may explain the high bone mass phenotype. As a result of the ECHO presentation, we decided that successful treatment of CKD-MBD would be the most effective approach to managing his bone fragility. His high bone mass phenotype was most likely associated with <em>LEMD3</em> gene variant. This patient does not require any specific anti-osteoporotic treatment at this time; however, he is likely to benefit from parathyroid surgery.</div></div>","PeriodicalId":50240,"journal":{"name":"Journal of Clinical Densitometry","volume":"28 1","pages":"Article 101554"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Densitometry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094695024000878","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Bone Health ECHO (Extension of Community Healthcare Outcomes) is a growing family of online educational programs. Its mission is to enhance delivery of best practice skeletal healthcare worldwide. Each program typically consists of a didactic lecture and discussion of clinical cases with diagnostic and treatment dilemmas. Here we present a Bone Health ECHO case of a 39-year-old man who has received hemodialysis for 12 years. This case is characterized by the development of chronic kidney disease - mineral and bone disorder (CKD-MBD) which was managed using conservative treatment to maintain phosphate and calcium levels within the reference range in spite of severe secondary hyperparathyroidism, after the patient declined parathyroidectomy. Although this patient had multiple vertebral fractures with height loss, his bone mineral density was higher than expected for his age and gradually increased over the period of observation. Whole-exome sequencing showed a heterozygous, likely pathogenic variant in LEMD3 gene (13 exon HG38, chr12:65246271dup, с.2682dup in a heterozygous state), which may explain the high bone mass phenotype. As a result of the ECHO presentation, we decided that successful treatment of CKD-MBD would be the most effective approach to managing his bone fragility. His high bone mass phenotype was most likely associated with LEMD3 gene variant. This patient does not require any specific anti-osteoporotic treatment at this time; however, he is likely to benefit from parathyroid surgery.
骨健康ECHO(社区医疗保健结果扩展)是一个正在成长的在线教育项目。其使命是加强全球骨骼保健最佳实践的交付。每个项目通常包括教学讲座和临床病例的诊断和治疗困境的讨论。在这里,我们提出了一个39岁的男性接受血液透析12年的骨健康回声病例。该病例的特点是慢性肾脏疾病-矿物质和骨骼疾病(CKD-MBD)的发展,尽管患者拒绝甲状旁腺切除术后出现严重的继发性甲状旁腺功能亢进,但仍采用保守治疗将磷酸盐和钙水平维持在参考范围内。虽然该患者有多处椎体骨折并伴有高度下降,但其骨密度高于同龄患者的预期,并在观察期间逐渐升高。全外显子组测序结果显示LEMD3基因(13外显子HG38, chr12:65246271dup, p < 0.05)存在杂合子,可能具有致病性。2682dup处于杂合状态),这可能解释了高骨量表型。根据ECHO的报告,我们认为CKD-MBD的成功治疗将是控制他骨骼脆弱性的最有效方法。其高骨量表型极有可能与LEMD3基因变异有关。该患者此时不需要任何特定的抗骨质疏松治疗;然而,他可能会从甲状旁腺手术中获益。
期刊介绍:
The Journal is committed to serving ISCD''s mission - the education of heterogenous physician specialties and technologists who are involved in the clinical assessment of skeletal health. The focus of JCD is bone mass measurement, including epidemiology of bone mass, how drugs and diseases alter bone mass, new techniques and quality assurance in bone mass imaging technologies, and bone mass health/economics.
Combining high quality research and review articles with sound, practice-oriented advice, JCD meets the diverse diagnostic and management needs of radiologists, endocrinologists, nephrologists, rheumatologists, gynecologists, family physicians, internists, and technologists whose patients require diagnostic clinical densitometry for therapeutic management.